INTRODUCTION:
Sept 8, 2023- an independent single-case evaluation study (also known as a PHASE ONE performance study) of the effects of a commercial skin topical product conducted by the Bard Diagnostic Imaging & Research Lab. The test drive was coordinated in part by the academic publishing and research administrators of the Integrative Health Research Center.
DISCLAIMER: This study is conducted as an impartial anecdotal test drive and report for public information. This product review was designed as an academic review of imaging technologies and the effect of the exosome-based product clinically supervised by Dr. Robert Bard (diagnostic imaging specialist and Sr. Research Advisor to HealthTech Reporter projects). This study is not in any way a commercial or marketing effort for the product(s) or technologies presented in this report. As an unbised/impartial review, it supports the implementation of quantitative imaging as the key platform for reporting on the physiological effects as induced.
COMPREHENSIVE PERFORMANCE REPORT OF A TOPICAL SKIN CONDITIONING PRODUCT
The following is an anecdotal performance report from a single academic case study to represent the effects of an exosome‐based topical product. Process and reaction reports collected were from the durations of July 25‐August 21 under the strict medical supervision of IHRC/ Bard Diagnostic Imaging Center. Quantitative imaging reports in this review were conducted strictly with the use of 3D Doppler Ultrasound imaging and Elastographic technology and are submitted by Dr. Robert L. Bard.
TOPICAL SERUM EFFICACY PERFORMANCE – RESEARCHER’S LOG
OVERVIEW:
Case study 1 of 1: the test subject is also a professional dermatologist who clinically identified disorders in the glabellar region (the smooth part of the forehead above and between the eyebrows) with skin roughness, itchiness and pigmented protrusions. Our research team established a base line with a sonogram scan labeled “DAY 1” at high resolution. The two short arrows point to the thickened epidermis, which is normally 200 microns and it is thickened to between 300 and 500 microns‐ as indicated by the arrows and the circle. Upon review, the tissue appears to be considerably swollen between the epidermis and the bone, and the inhomogeneous echo pattern is filled with dilated subdermal glands. The significance of this is that the surface of a skin lesion in inflammatory diseases is dependent upon the subsurface or subcutaneous pathology, which is often not visible with the naked eye.
In this case, after 27 days of using the product three times a day, we noticed that the arrow at day 27 points to the 200 micron epidermis and the swelling has greatly reduced, and the internal subcutaneous echo pattern is more homogeneous with fewer dilated glandular regions. From the user’s perspective, the volunteer expressed significant satisfaction after one month of progress and is now continuing use of the product with a 2nd bottle.
Global interest in the advancement of Exosomes continues to raise significant interest in the research community to explore and confirm findings about this technology as has been raised since the advent of stem cell research (early 1980’s). Dr. Robert Bard initiated this “test drive” employing an IMAGE-GUIDED approach to monitor, track and report his findings through the use of advanced ultrasound scanning modalities.
IMAGING TRANSDUCER/PROBE TECHNOLOGY & SCAN INTERPRETATION: On day #1, we used a 33MHz ultra‐high resolution probe. On day #27, because the roughness and puffiness of the skin had reduced, we use a 20MHz probe. What's important is the dermis is clearly seen to have two layers; one is a dark gray layer which is represented by the single arrow that points to the epidermis. Below that is a white layer‐ which is the bottom layer of the epidermis. This is indicative of a collagen disease or inflammatory disease process and the epidermis, which still continues, but the irregularity in the epidermis and the dilated inflammatory glands have decreased dramatically.
PART 2: A supplemental test is to expand this line of research to detect and measure the vascular effects of the inflammation with the 3D Doppler histogram technology. This ultrasound feature is often used to quantify the inflammatory vascularity. In this case study, we are able to detect intradermal hyperemia and inflammatory vascularity.
STRATEGIC TARGETING OF INFLAMMATION
Most inflammatory diseases are subdermal or dermal and are not visually evident with the unaided eye. Use of the sonogram clearly shows measurable epidermal thickening and irregularity. Our diagnostic scanning indicated subdermal dilated glands and cystic areas which are related to the inflammatory process. While quantitative imaging helps us identify the cosmetic effects of exosomes with this product, confirming this with the patient’s reported reduction of itching (or pruritus reduction) aligns with the product’s anti‐inflammatory effect. This is a conceivable indicator of the depth of penetration of this product from the surface to the subcutaneous tissues, offering potential validation of the therapeutic effects of this product.
# # #
For this research project, the research imaging director opted to advance the quantitative data gathering by employing the elastogram feature of the ultrasound system. Dr. Bard's research sought the functionality of the CANON APLIO i800. Thanks to Canon's expansive collection of transducers (probes), scanning the epidermal area was made possible in pursuit of physiological reactions to the patient's exposure to the topical exosome serum.
SPECIAL THANKS
IHRC and Health Tech Reporter wish to give special thanks to all the clinical technicians and volunteers who offered their time and support in completing this performance test study. We also express our deep appreciation to the generosity and innovative brilliance of Dr. Jordan R. Plews, Co-founder & CEO of ELEVAI Labs, Inc. for his remarkable product(s), his clinical guidance and his scientific tour of the ELEVAI product development which greatly inspired the strategic planning behind this phase 1 study. Further thanks to Mr. Michael Wetter, Ultrasound Regional Business Manager of Canon Medical Systems USA, Inc. for their professional support in the facilitation and use of their imaging technology and further education in ultrasound advancement. Additional thanks belong to Abdellatif Zerzif (ultrasound & laser tech) for his stellar professional performance in managing both technologies and patient care. Major thanks belong to clinical and diagnostic talents of Dr. Robert Bard as well as reporters Lennard Gettz, Dr. Noelle Cutter, Dr. Roberta Kline and Dr. Leslie Valle-Montoya for their research structure and coordination throughout the execution of this project, including the development of this final report.
10/25 - Dr. Robert Bard's presentation has been approved for the Inflammatory Skin Disease Summit 2023 in Vienna from November 15-18, 2023. The conference will be accommodated at the Austrian Academy of Sciences (Aula der Wissenschaften). This world conference welcomes experts in the medical community to discuss new concepts and new developments in the field of inflammatory skin diseases and to devise and explore new therapeutic strategies. The ISDS is promoted by the ESDR- European Society for Dermatological Research, an institute committed to the education and training of the next generation of skin researchers and to promote the highest quality skin research. The expertise that resides within the ESDR community is immense from skin research centers to individuals.
 |
| 2022 Events Courtesy of Bardvideos.com |
Dr. Bard's latest presentation to be delivered at the ISDS conference is the "ABSCOPAL EFFECTS OF IMAGE GUIDED PULSED BIOENERGY TREATMENT WITH VIRTUAL BIOPSY". His report explores adjuvant treatment effects of modern and non-invasive therapeutic solutions such as pulsed near infrared laser and pulsed electromagnetic therapy irradiation (PEMF) and their potential in invoking an “abscopal effect,” which occurs when the primary site is irradiated, and regression of non-irradiated sites are observed.
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to in-depth understanding of skin homeostasis and towards improving the health of patients suffering from skin and venereal disease, infectious diseases and immune-mediated and inflammatory disorders. Applications of recent scientific advances have produced diagnostic and therapeutic innovations in dermatological practice, particularly in genetics, skin cancer, allergic skin disease, infectious disease and autoimmune diseases.
No comments:
Post a Comment